Lateral flow immunoassays for SARS-CoV-2
The continued circulation of SARS-CoV-2 virus in different parts of the world opens up the possibility for more virulent variants to evolve even as the coronavirus disease 2019 transitions from pandemic to endemic. Highly transmissible and virulent variants may seed new disruptive epidemic waves tha...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
MDPI AG
2022
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/102079/ |
| _version_ | 1848863708617375744 |
|---|---|
| author | Ang, Geik Yong Chan, Kok Gan Yean, Chan Yean Yu, Choo Yee |
| author_facet | Ang, Geik Yong Chan, Kok Gan Yean, Chan Yean Yu, Choo Yee |
| author_sort | Ang, Geik Yong |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | The continued circulation of SARS-CoV-2 virus in different parts of the world opens up the possibility for more virulent variants to evolve even as the coronavirus disease 2019 transitions from pandemic to endemic. Highly transmissible and virulent variants may seed new disruptive epidemic waves that can easily put the healthcare system under tremendous pressure. Despite various nucleic acid-based diagnostic tests that are now commercially available, the wide applications of these tests are largely hampered by specialized equipment requirements that may not be readily available, accessible and affordable in less developed countries or in low resource settings. Hence, the availability of lateral flow immunoassays (LFIs), which can serve as a diagnostic tool by detecting SARS-CoV-2 antigen or as a serological tool by measuring host immune response, is highly appealing. LFI is rapid, low cost, equipment-free, scalable for mass production and ideal for point-of-care settings. In this review, we first summarize the principle and assay format of these LFIs with emphasis on those that were granted emergency use authorization by the US Food and Drug Administration followed by discussion on the specimen type, marker selection and assay performance. We conclude with an overview of challenges and future perspective of LFI applications. |
| first_indexed | 2025-11-15T13:37:13Z |
| format | Article |
| id | upm-102079 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-15T13:37:13Z |
| publishDate | 2022 |
| publisher | MDPI AG |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-1020792023-06-08T02:27:59Z http://psasir.upm.edu.my/id/eprint/102079/ Lateral flow immunoassays for SARS-CoV-2 Ang, Geik Yong Chan, Kok Gan Yean, Chan Yean Yu, Choo Yee The continued circulation of SARS-CoV-2 virus in different parts of the world opens up the possibility for more virulent variants to evolve even as the coronavirus disease 2019 transitions from pandemic to endemic. Highly transmissible and virulent variants may seed new disruptive epidemic waves that can easily put the healthcare system under tremendous pressure. Despite various nucleic acid-based diagnostic tests that are now commercially available, the wide applications of these tests are largely hampered by specialized equipment requirements that may not be readily available, accessible and affordable in less developed countries or in low resource settings. Hence, the availability of lateral flow immunoassays (LFIs), which can serve as a diagnostic tool by detecting SARS-CoV-2 antigen or as a serological tool by measuring host immune response, is highly appealing. LFI is rapid, low cost, equipment-free, scalable for mass production and ideal for point-of-care settings. In this review, we first summarize the principle and assay format of these LFIs with emphasis on those that were granted emergency use authorization by the US Food and Drug Administration followed by discussion on the specimen type, marker selection and assay performance. We conclude with an overview of challenges and future perspective of LFI applications. MDPI AG 2022-11-18 Article PeerReviewed Ang, Geik Yong and Chan, Kok Gan and Yean, Chan Yean and Yu, Choo Yee (2022) Lateral flow immunoassays for SARS-CoV-2. Diagnostics, 12 (11). art. no. 2854. pp. 1-22. ISSN 0336-3449 https://www.mdpi.com/2075-4418/12/11/2854 10.3390/diagnostics12112854 |
| spellingShingle | Ang, Geik Yong Chan, Kok Gan Yean, Chan Yean Yu, Choo Yee Lateral flow immunoassays for SARS-CoV-2 |
| title | Lateral flow immunoassays for SARS-CoV-2 |
| title_full | Lateral flow immunoassays for SARS-CoV-2 |
| title_fullStr | Lateral flow immunoassays for SARS-CoV-2 |
| title_full_unstemmed | Lateral flow immunoassays for SARS-CoV-2 |
| title_short | Lateral flow immunoassays for SARS-CoV-2 |
| title_sort | lateral flow immunoassays for sars-cov-2 |
| url | http://psasir.upm.edu.my/id/eprint/102079/ http://psasir.upm.edu.my/id/eprint/102079/ http://psasir.upm.edu.my/id/eprint/102079/ |